[{"id":"6a7737ea-7363-4409-b641-c11409e515ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04181060","created_at":"2021-01-18T20:23:16.793Z","updated_at":"2025-02-25T12:37:29.255Z","phase":"Phase 3","brief_title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","source_id_and_acronym":"NCT04181060","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-24"},{"id":"9de3eb66-06bd-4d1a-92a9-adae61b8b59a","acronym":"Acclaim-1","url":"https://clinicaltrials.gov/study/NCT04486833","created_at":"2021-01-18T21:32:20.912Z","updated_at":"2025-02-25T12:27:38.683Z","phase":"Phase 1/2","brief_title":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","source_id_and_acronym":"NCT04486833 - Acclaim-1","lead_sponsor":"Genprex, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • carboplatin • Reqorsa (quaratusugene ozeplasmid)"],"overall_status":"Recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 09/03/2021","start_date":" 09/03/2021","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-02-24"},{"id":"e7f1cf47-55e5-465b-a0d2-cff0dfd74a56","acronym":"","url":"https://clinicaltrials.gov/study/NCT03191149","created_at":"2021-01-18T15:44:05.558Z","updated_at":"2025-02-25T12:26:43.341Z","phase":"Phase 2","brief_title":"Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change","source_id_and_acronym":"NCT03191149","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 04/25/2018","start_date":" 04/25/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-24"},{"id":"1a5d5c5e-2d0c-4820-8c6b-6f33f98d1419","acronym":"INSIGHT 2","url":"https://clinicaltrials.gov/study/NCT03940703","created_at":"2021-01-18T19:24:17.010Z","updated_at":"2025-02-25T13:52:54.712Z","phase":"Phase 2","brief_title":"A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)","source_id_and_acronym":"NCT03940703 - INSIGHT 2","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • MET amplification","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Tepmetko (tepotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 09/19/2019","start_date":" 09/19/2019","primary_txt":" Primary completion: 05/11/2023","primary_completion_date":" 05/11/2023","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-20"},{"id":"961758d0-6679-4971-b806-6a0fe59d5b35","acronym":"ROSE","url":"https://clinicaltrials.gov/study/NCT05089916","created_at":"2021-10-22T12:53:07.379Z","updated_at":"2025-02-25T14:41:02.334Z","phase":"Phase 2","brief_title":"Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study","source_id_and_acronym":"NCT05089916 - ROSE","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/20/2022","start_date":" 01/20/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-14"},{"id":"cd480536-5f7e-444d-af5e-6fed1b7c13bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04410796","created_at":"2021-01-18T21:16:01.585Z","updated_at":"2025-02-25T14:40:36.515Z","phase":"Phase 2","brief_title":"Osimertinib Alone or with Chemotherapy for EGFR-Mutant Lung Cancers","source_id_and_acronym":"NCT04410796","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carboplatin • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 571","initiation":"Initiation: 05/28/2020","start_date":" 05/28/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-02-14"},{"id":"6443d84d-18f2-435e-a44c-d58932c7c829","acronym":"SKB264-II-04","url":"https://clinicaltrials.gov/study/NCT05816252","created_at":"2023-04-18T15:04:37.057Z","updated_at":"2025-02-25T15:20:25.216Z","phase":"Phase 2","brief_title":"A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05816252 - SKB264-II-04","lead_sponsor":"Klus Pharma Inc.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tagrisso (osimertinib) • carboplatin • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 498","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2025-02-12"},{"id":"875dde5d-a068-44c0-a533-8d1880dcc9a8","acronym":"MARIPOSA","url":"https://clinicaltrials.gov/study/NCT04487080","created_at":"2021-01-18T21:32:24.291Z","updated_at":"2025-02-25T15:18:45.913Z","phase":"Phase 3","brief_title":"A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04487080 - MARIPOSA","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1074","initiation":"Initiation: 09/30/2020","start_date":" 09/30/2020","primary_txt":" Primary completion: 08/11/2023","primary_completion_date":" 08/11/2023","study_txt":" Completion: 06/29/2027","study_completion_date":" 06/29/2027","last_update_posted":"2025-02-12"},{"id":"2e21d46a-4d04-455d-bf00-12d45552b4d9","acronym":"OSIREAL","url":"https://clinicaltrials.gov/study/NCT06068049","created_at":"2024-01-05T15:17:15.046Z","updated_at":"2025-02-25T15:28:21.321Z","phase":"","brief_title":"OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain","source_id_and_acronym":"NCT06068049 - OSIREAL","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 07/28/2023","start_date":" 07/28/2023","primary_txt":" Primary completion: 06/15/2029","primary_completion_date":" 06/15/2029","study_txt":" Completion: 06/15/2029","study_completion_date":" 06/15/2029","last_update_posted":"2025-02-11"},{"id":"5f3b5bbb-9aff-4571-a252-57e8a1171808","acronym":"CHRYSALIS-2","url":"https://clinicaltrials.gov/study/NCT04077463","created_at":"2021-01-18T19:58:05.927Z","updated_at":"2025-02-25T15:34:28.760Z","phase":"Phase 1","brief_title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04077463 - CHRYSALIS-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 701","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 02/03/2025","primary_completion_date":" 02/03/2025","study_txt":" Completion: 06/03/2026","study_completion_date":" 06/03/2026","last_update_posted":"2025-02-11"},{"id":"d34aa307-ae7e-44e1-9d9a-f7de8a535562","acronym":"PALOMA-2","url":"https://clinicaltrials.gov/study/NCT05498428","created_at":"2022-08-19T18:11:07.577Z","updated_at":"2025-02-25T15:19:56.526Z","phase":"Phase 2","brief_title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05498428 - PALOMA-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 08/05/2026","study_completion_date":" 08/05/2026","last_update_posted":"2025-02-11"},{"id":"242a6457-aef1-4b8b-890a-953bd32e515a","acronym":"SAVANNAH","url":"https://clinicaltrials.gov/study/NCT03778229","created_at":"2021-01-18T18:41:19.683Z","updated_at":"2025-02-25T15:34:16.664Z","phase":"Phase 2","brief_title":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","source_id_and_acronym":"NCT03778229 - SAVANNAH","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 367","initiation":"Initiation: 01/09/2019","start_date":" 01/09/2019","primary_txt":" Primary completion: 08/23/2024","primary_completion_date":" 08/23/2024","study_txt":" Completion: 05/28/2025","study_completion_date":" 05/28/2025","last_update_posted":"2025-02-10"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"1d4264b1-4ecd-48a1-88aa-d47b1b9d9638","acronym":"","url":"https://clinicaltrials.gov/study/NCT03810807","created_at":"2021-01-18T18:49:46.476Z","updated_at":"2025-02-25T16:52:25.068Z","phase":"Phase 1","brief_title":"Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer","source_id_and_acronym":"NCT03810807","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Vizimpro (dacomitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-04"},{"id":"06aea852-4f4f-4fb7-987b-2400ee6b5c52","acronym":"ORBITAL","url":"https://clinicaltrials.gov/study/NCT04233021","created_at":"2021-01-18T20:35:29.375Z","updated_at":"2025-02-25T17:00:23.523Z","phase":"Phase 2","brief_title":"Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation","source_id_and_acronym":"NCT04233021 - ORBITAL","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 07/16/2020","start_date":" 07/16/2020","primary_txt":" Primary completion: 03/15/2023","primary_completion_date":" 03/15/2023","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2025-02-03"},{"id":"ece1e947-6ee1-43ee-ad69-399f7ff3106a","acronym":"CoC","url":"https://clinicaltrials.gov/study/NCT04606771","created_at":"2021-01-19T20:31:36.655Z","updated_at":"2025-02-25T17:00:42.361Z","phase":"Phase 2","brief_title":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","source_id_and_acronym":"NCT04606771 - CoC","lead_sponsor":"AstraZeneca","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/28/2020","start_date":" 09/28/2020","primary_txt":" Primary completion: 12/21/2022","primary_completion_date":" 12/21/2022","study_txt":" Completion: 03/28/2025","study_completion_date":" 03/28/2025","last_update_posted":"2025-02-03"},{"id":"0ce6edde-72a4-4b16-a147-428d02d9773d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03433469","created_at":"2021-01-18T16:56:11.530Z","updated_at":"2025-02-25T14:58:42.444Z","phase":"Phase 2","brief_title":"Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery","source_id_and_acronym":"NCT03433469","lead_sponsor":"University of California, San Francisco","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 07/31/2018","start_date":" 07/31/2018","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2025-01-31"},{"id":"75b550a9-d016-442f-8549-62ab7dd6a2fd","acronym":"AZENT","url":"https://clinicaltrials.gov/study/NCT02841579","created_at":"2021-01-18T13:56:52.079Z","updated_at":"2025-02-25T15:07:10.729Z","phase":"Phase 2","brief_title":"Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M","source_id_and_acronym":"NCT02841579 - AZENT","lead_sponsor":"MedSIR","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/02/2016","start_date":" 09/02/2016","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 02/14/2020","study_completion_date":" 02/14/2020","last_update_posted":"2025-01-28"},{"id":"24d56592-fb8d-46ea-9576-a63025e1a603","acronym":"STU 122017-017","url":"https://clinicaltrials.gov/study/NCT03667820","created_at":"2021-01-18T17:59:42.946Z","updated_at":"2025-02-25T15:07:55.003Z","phase":"Phase 2","brief_title":"Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC","source_id_and_acronym":"NCT03667820 - STU 122017-017","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 09/26/2018","start_date":" 09/26/2018","primary_txt":" Primary completion: 03/30/2025","primary_completion_date":" 03/30/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-12-27"},{"id":"96561c74-893b-4a20-840e-ad82df20e4f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03586453","created_at":"2021-01-18T17:38:23.084Z","updated_at":"2025-02-25T15:07:45.363Z","phase":"Phase 2","brief_title":"Osimertinib In EGFR Mutant Lung Cancer","source_id_and_acronym":"NCT03586453","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-11-19"},{"id":"eca89281-345b-4922-b035-d805f889120c","acronym":"NCI-2018-02010","url":"https://clinicaltrials.gov/study/NCT03732352","created_at":"2021-01-18T18:16:58.787Z","updated_at":"2025-02-25T15:08:03.210Z","phase":"Phase 2","brief_title":"18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma","source_id_and_acronym":"NCT03732352 - NCI-2018-02010","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" EGFR • TP53","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification","tags":["EGFR • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 11/28/2018","start_date":" 11/28/2018","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2024-11-12"},{"id":"e223a1f5-d09a-4fd9-81f5-04314449ae99","acronym":"","url":"https://clinicaltrials.gov/study/NCT03769103","created_at":"2021-01-18T18:38:55.062Z","updated_at":"2025-02-25T15:08:09.395Z","phase":"Phase 2","brief_title":"Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC","source_id_and_acronym":"NCT03769103","lead_sponsor":"British Columbia Cancer Agency","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/19/2019","start_date":" 03/19/2019","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-10-31"},{"id":"c2c36ee0-307e-4127-9eff-977434e32bf6","acronym":"OCELOT","url":"https://clinicaltrials.gov/study/NCT04335292","created_at":"2021-01-18T20:59:24.421Z","updated_at":"2025-02-25T14:58:59.418Z","phase":"Phase 2","brief_title":"Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge","source_id_and_acronym":"NCT04335292 - OCELOT","lead_sponsor":"Mark Vincent","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/06/2021","start_date":" 01/06/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-10-22"},{"id":"be216cac-b6dd-4109-a60b-83756637bfdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03122717","created_at":"2021-01-17T17:16:14.303Z","updated_at":"2025-02-25T14:58:00.620Z","phase":"Phase 1/2","brief_title":"Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer","source_id_and_acronym":"NCT03122717","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • gefitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 05/09/2017","start_date":" 05/09/2017","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-09-26"}]